Clinical Trial evaluating the correlation of clinical efficacy of alternative antiandrogens and UFT therapy with mRNA expression of enzymes related to 5-FU metabolism in patients with prostate cancer who relapsed after maximum androgen blockade
Phase 2
- Conditions
- Castration-resistant prostate cancer
- Registration Number
- JPRN-UMIN000004203
- Lead Sponsor
- Department of Urology, Institute of Health Biosciences, The University of Tokushima Graduate School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 68
Inclusion Criteria
Not provided
Exclusion Criteria
1.past history of radiotherapy or prostatectomy 2.past history of allergic reactions 3.use phenytoin 4.contraindication of UFT 5.active infection 6.serious complications 7.other cancer requiring treatment 8.judged inappropriate for the clinical trial by doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link antiandrogen efficacy to 5-FU metabolism enzymes in castration-resistant prostate cancer?
How does UFT therapy compare to standard-of-care treatments for post-androgen blockade prostate cancer relapse?
Which mRNA biomarkers predict response to alternative antiandrogens in castration-resistant prostate cancer patients?
What adverse events are associated with UFT and antiandrogen combination therapy in prostate cancer?
Are there synergistic effects between 5-FU metabolism modulators and next-generation antiandrogens in CRPC treatment?